LOS
GATOS, Calif., June 3, 2022
/PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a
biopharmaceutical company focused on the discovery and development
of novel anti-infective therapies to treat life-threatening
infections, today announced that Vu
Truong, Ph.D., Chief Executive Officer of Aridis
Pharmaceuticals, will participate in a virtual fireside chat
presented by Maxim Group LLC and hosted by M-Vest on June 7 at 11 a.m.
ET. Investors who wish to join the Fireside Chat can
register for a free M-Vest membership using the link to the webcast
below.
Event:
|
Fireside Chat with
Aridis Pharmaceuticals, Inc.
|
Date/ Time:
|
Tuesday, June 7, 2022,
at 11:00 am ET
|
Webcast:
|
Click here to
register
|
During the fireside chat, moderated by Maxim Group Research
Analyst Jason McCarthy, Dr. Truong
is expected to provide an overview of Aridis' late-stage
development pipeline and anticipated upcoming data readout
timelines.
About Aridis Pharmaceuticals, Inc.
Aridis Pharmaceuticals, Inc. discovers and develops
anti-infectives to be used as first-line treatments to combat
antimicrobial resistance (AMR) and viral pandemics. The Company is
utilizing its proprietary ʎPEX and MabIgX® technology
platforms to rapidly identify rare, potent antibody-producing
B-cells from patients who have successfully overcome an infection,
and to rapidly manufacture mAbs for therapeutic treatment of
critical infections. These mAbs are already of human origin and
functionally optimized by the natural human immune system for high
potency. Hence, they are already fit-for-purpose and do not require
further engineering optimization to achieve full functionality.
The Company has generated multiple clinical stage mAbs targeting
bacteria that cause life-threatening infections such as ventilator
associated pneumonia (VAP) and hospital acquired pneumonia (HAP),
in addition to preclinical stage antibacterial and antiviral mAbs.
The use of mAbs as anti-infective treatments represents an
innovative therapeutic approach that harnesses the human immune
system to fight infections and is designed to overcome the
deficiencies associated with the current standard of care, which is
broad spectrum antibiotics. Such deficiencies include, but are not
limited to, increasing drug resistance, short duration of efficacy,
disruption of the normal flora of the human microbiome and lack of
differentiation among current treatments. The mAb portfolio is
complemented by a non-antibiotic novel mechanism small molecule
anti-infective candidate being developed to treat lung infections
in cystic fibrosis patients. The Company's pipeline is highlighted
below:
Aridis' Pipeline
AR-301 (VAP). AR-301 is a fully human IgG1 mAb
currently in Phase 3 clinical development targeting
gram-positive Staphylococcus aureus (S.
aureus) alpha-toxin in VAP patients.
AR-320 (nosocomial pneumonia). AR-320 is a
fully human mAb targeting S. aureus alpha-toxin for
prevention of nosocomial pneumonia. Statistically significant Phase
2 data in the target population of those ≤ 65 years of age was
published in the September 2021
Lancet Infectious Diseases journal. The Company has completed
discussions with the EMA and FDA on study design and expects to
launch its Phase 3 study of AR-320 in mid-2022.
AR-101 (HAP). AR-101 is a fully human
immunoglobulin M (IgM) mAb in Phase 2 clinical development
targeting Pseudomonas aeruginosa (P.
aeruginosa) liposaccharides serotype O11, which accounts
for approximately 22% of all P.
aeruginosa hospital acquired pneumonia cases worldwide.
This program is licensed to the Serum Institute of India and Shenzhen Arimab.
AR-501 (cystic fibrosis). AR-501 is an inhaled
formulation of gallium citrate with broad-spectrum anti-infective
activity being developed to treat chronic lung infections in cystic
fibrosis patients. This program is currently in a Phase 2a
clinical study in CF patients.
AR-701 (COVID-19). AR-701 is a cocktail of fully
human mAbs discovered from convalescent COVID-19 patients that are
directed at multiple envelope proteins of the SARS-CoV-2 virus.
AR-401 (blood stream infections). AR-401 is a
fully human mAb preclinical program aimed at treating infections
caused by gram-negative Acinetobacter baumannii.
AR-201 (RSV infection). AR-201 is a fully human IgG1
mAb directed against the F-protein of diverse clinical isolates of
respiratory syncytial virus (RSV). This program is licensed
exclusively to the Serum Institute of India.
For additional information on Aridis Pharmaceuticals, please
visit https://aridispharma.com/.
Forward-Looking Statements
Certain statements in this press release are forward-looking
statements that involve a number of risks and
uncertainties. These statements may be identified by the use
of words such as "anticipate," "believe," "forecast," "estimated"
and "intend" or other similar terms or expressions that concern
Aridis' expectations, strategy, plans or intentions. These
forward-looking statements are based on Aridis' current
expectations and actual results could differ materially.
There are a number of factors that could cause actual events
to differ materially from those indicated by such forward-looking
statements. These factors include, but are not limited to,
the need for additional financing, the timing of regulatory
submissions, Aridis' ability to obtain and maintain regulatory
approval of its existing product candidates and any other product
candidates it may develop, approvals for clinical trials may be
delayed or withheld by regulatory agencies, risks relating to the
timing and costs of clinical trials, risks associated with
obtaining funding from third parties, management and employee
operations and execution risks, loss of key personnel, competition,
risks related to market acceptance of products, intellectual
property risks, risks related to business interruptions, including
the outbreak of COVID-19 coronavirus, which could seriously harm
our financial condition and increase our costs and expenses, risks
associated with the uncertainty of future financial results,
Aridis' ability to attract collaborators and partners and risks
associated with Aridis' reliance on third party
organizations. While the list of factors presented here is
considered representative, no such list should be considered to be
a complete statement of all potential risks and uncertainties.
Unlisted factors may present significant additional obstacles to
the realization of forward-looking statements. Actual results could
differ materially from those described or implied by such
forward-looking statements as a result of various important
factors, including, without limitation, market conditions and the
factors described under the caption "Risk Factors" in Aridis' 10-K
for the year ended December 31, 2021,
and Aridis' other filings made with the Securities and Exchange
Commission. Forward-looking statements included herein are
made as of the date hereof, and Aridis does not undertake any
obligation to update publicly such statements to reflect subsequent
events or circumstances.
Contact:
Investor Relations
Dave Gentry, CEO
RedChip Companies
ARDS@redchip.com
SOURCE Aridis Pharmaceuticals, Inc.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/aridis-pharmaceuticals-ceo-to-participate-in-a-fireside-chat-presented-by-maxim-group-llc-and-hosted-by-m-vest-on-june-7-301560877.html
SOURCE Aridis Pharmaceuticals, Inc.